Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease.

Abstract

AIM:

In statin-treated persons with atherosclerotic cardiovascular disease (ASCVD) the further ASCVD risk that diabetes mellitus (DM) adds is not well-quantified. We examined this residual risk for initial and total recurrent ASCVD events.

METHODS:

We studied 3271 patients with ASCVD on statin therapy in the AIM-HIGH clinical trial cohort. Cox regression and the Prentice, Williams, and Peterson model examined the excess risk of initial and total recurrent ASCVD events associated with DM over a 3- year mean follow-up. Predictors of first and total ASCVD events in those with and without DM were also examined.

RESULTS:

Of our cohort with ASCVD on statin therapy 40% also had DM. Those with vs. without DM were older, were less likely to be male or white. They had higher systolic blood pressure, lower HDL-C, LDL-C, lipoprotein (a), but higher triglycerides and BMI (all p < 0.01). Adjusted HRs were 1.21 (95% CI; 1.01-1.46, p = 0.038) and 1.23 (95% CI: 1.05-1.44, p = 0.012) for first and total recurrent ASCVD events, respectively. Homocysteine and lipoprotein(a) most strongly predicted events in those with and without DM, respectively.

CONCLUSION:

In statin-treated patients with ASCVD, DM was associated with significantly greater residual risk over ASCVD alone for both first and total recurrent ASCVD events.

• Authors: Yanglu Zhao, Pin Xiang, Blai Coll, J Antonio G López, Nathan D Wong
• Journal: Journal of diabetes and its complications (J Diabetes Complications) Vol. 35 Issue 3 Pg. 107767 (03 2021) ISSN: 1873-460X [Electronic] United States
• PMID: 33168394 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 Elsevier Inc. All rights reserved.

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Lipoprotein(a)

Topics

• Atherosclerosis (complications, epidemiology, prevention & control)
• Cardiovascular Diseases (complications, epidemiology, prevention & control)
• Cohort Studies
• Diabetes Complications
• Diabetes Mellitus
• Female
• Heart Disease Risk Factors
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Lipoprotein(a)
• Male
• Risk Assessment
• Risk Factors